58
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD – subgroup analysis of the Taiwan obstructive lung disease cohort

, , , , , , , , , , & show all
Pages 1951-1956 | Published online: 14 Sep 2015

References

  • HsiaoAJChenLHLuTHTen leading causes of death in Taiwan: a comparison of two grouping listsJ Formos Med Assoc Epub1202014
  • WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
  • VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
  • CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
  • de Miguel-DiezJCarrasco-GarridoPRejas-GutierrezJInappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health statusLung2011189319920621499887
  • WhitePThorntonHPinnockHGeorgopoulouSBoothHPOver-treatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
  • KoblizekVPecenLZatloukalJReal-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatmentPLoS One2014911e11107825380287
  • ThomasMRadwanAStonhamCMarshallSCOPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary careCOPD201411330030924152210
  • VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
  • NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting β2-agonist in one inhaler versus long-acting β2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00682922972099
  • FesticEScanlonPDIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Am J Respir Crit Care Med2015191214114825409118
  • ChoudhuryABDawsonCMKilvingtonHEWithdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trialRespir Res200789318162137
  • van der ValkPMonninkhofEvan der PalenJZielhuisGvan HerwaardenCEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med2002166101358136312406823
  • WoutersEFPostmaDSFokkensBWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
  • RossiAGuerrieroMCorradoAWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
  • MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
  • KunzLIPostmaDSKloosterKRelapse in FEV1-decline after steroid withdrawal in chronic obstructive pulmonary diseaseChest Epub422015
  • PapaiwannouAZarogoulidisPPorpodisKAsthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature reviewJ Thorac Dis20146Suppl 1S146S15124672688
  • JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD assessment testEur Respir J200934364865419720809